Results 181 to 190 of about 1,015,438 (326)
Activation of the mitochondrial protein OXR1 increases pSyn129 αSynuclein aggregation by lowering ATP levels and altering mitochondrial membrane potential, particularly in response to MSA‐derived fibrils. In contrast, ablation of the ER protein EMC4 enhances autophagic flux and lysosomal clearance, broadly reducing α‐synuclein aggregates.
Sandesh Neupane +11 more
wiley +1 more source
Fault-tolerant quantum computation without distillation on a 2D device. [PDF]
Scruby TR, Nemoto K, Cai Z.
europepmc +1 more source
Data and code for "A Linear Time Solution to the Labeled Robinson-Foulds Distance Problem"
Samuel Briand +3 more
openalex +1 more source
Intercompartmental communication in senescence
Senescent cells experience structural changes in the plasma membrane, endoplasmic reticulum, mitochondria, lysosomes, nucleus, and cytoskeleton. These alterations disrupt crosstalk among cellular compartments, impairing vesicular trafficking, contact sites, and molecular flow.
Krystyna Mazan‐Mamczarz +3 more
wiley +1 more source
RL-Based Parallel LDPC Decoding with Clustered Scheduling. [PDF]
Ozkan Y, Yakimenka Y, Kliewer J.
europepmc +1 more source
Long‐Term Follow‐Up of Chemotherapy‐Associated Biological Aging in Women With Early Breast Cancer
Women threated with adjuvant chemotherapy for early breast cancer have sustained long‐term increase in p16INK4a,, a robust marker of cell senescence, suggesting a chemotherapy‐associated age acceleration. p16INK4a as well as other biomarkers may identify patients at greatest risk for senescence‐related diseases of aging.
Hyman B. Muss +12 more
wiley +1 more source
A New Method of Analysing Sprint, Deceleration, and Change of Direction Abilities in Trained Athletes. [PDF]
Gordon G, Green A.
europepmc +1 more source
Instantly Decodable versus Random Linear Network Coding: A Comparative Framework for Throughput and Decoding Delay Performance [PDF]
Parastoo Sadeghi, Mingchao Yu
openalex +1 more source
Real‐World Investigation of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disease
ABSTRACT Objective Satralizumab, a monoclonal antibody targeting the interleukin‐6 receptor, has demonstrated efficacy in clinical trials for neuromyelitis optica spectrum disorder (NMOSD). However, its real‐world effectiveness and safety compared to conventional immunosuppressive therapies remain uncertain.
Li‐Tsung Lin +2 more
wiley +1 more source

